Abstract
Antigen-loaded dendritic cells (DCs) have been intensively investigated as potential cellular antitumor vaccines. Several recent reports have indicated that loading DCs with whole tumor derived mRNA or defined tumor-antigen-encoding mRNA represents an effective nonviral strategy to stimulate T cell responses both for in vitro and in vivo models. Here, we describe the electroporation method as a tool for introducing in vitro transcribed capped mRNA into human DCs for tumor vaccination. We use MART-1/Melan-A as a model tumor-associated antigen for the generation of a DC-based vaccine against melanoma cancer. In addition to efficient antigen loading, it is important to obtain a maximal number of potent antigen-presenting cells. Another prerequisite for the development of a DC-based cancer vaccine is to obtain mature DCs. In this chapter, we describe the basic techniques required for the successful genetic modification of DCs by using the mRNA electroporation method.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
1. Steinman, R.M. and Dhodapkar, M. (2001) Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer. 94, 459–473.
2. Banchereau, J., Schuler-Thurner, B., Palucka, A.K., and Schuler, G. (2001) Dendritic cells as vectors for therapy. Cell. 106, 271–274.
3. Tuyaerts, S., Noppe, S.M., Corthals, J., et al. (2002) Generation of large numbers of dendritic cells in a closed system using Cell Factories. J. Immunol. Methods. 264, 135–151.
4. Mitchell, D.A. and Nair, S.K. (2000) RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106, 1065–1069.
5. Ponsaerts, P., Van Tendeloo, V.F., and Berneman, Z.N. (2003) Cancer immunotherapy using RNA-loaded dendritic cells. Clin. Exp. Immunol. 134, 378–384.
6. Bonehill, A., Heirman, C., Tuyaerts, S., et al. (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 172, 6649–6657.
7. Van Tendeloo, V.F., Ponsaerts, P., Lardon, F., et al. (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 98, 49–56.
8. Tuyaerts, S., Michiels, A., Corthals, J., et al. (2003) Induction of influenza matrix protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther. 10, 696–706.
9. Bonehill, A., Heirman, C., Tuyaerts, S., et al. (2003) Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res. 63, 5587–5594.
10. Michiels, A., Tuyaerts, S., Bonehill, A., et al.(2005) Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. 12, 772–782.
11. Michiels, A., Breckpot, K., Corthals, J., et al. (2006) Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther. 13, 1027–1036.
12. Grunebach, F., Kayser, K., Weck, M.M., Muller, M.R., Appel, S., and Brossart, P. (2005) Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther. 12, 749–756.
13. Dannull, J., Nair, S., Su, Z., et al. (2005) Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood. 105, 3206–3213.
14. Mockey, M., Gonçalves, C., Dupuy, F.P., Lemoine, F.M., Pichon, C., and Midoux, P. (2006) mRNA transfection of dendritic cells: Synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem. Biophys. Res. Commun. 340, 1062–1068.
15. Reichardt V.L., Brossart, P., and Kanz, L. (2004) Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 18, 235–243.
16. Valmori, D., Fonteneau, J.F., Lizana C.M., et al. (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160, 1750–1758.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press
About this protocol
Cite this protocol
Michiels, A., Tuyaerts, S., Bonehill, A., Heirman, C., Corthals, J., Thielemans, K. (2008). Delivery of Tumor-Antigen-Encoding mRNA into Dendritic Cells for Vaccination. In: Li, S. (eds) Electroporation Protocols. Methods in Molecular Biology™, vol 423. Humana Press. https://doi.org/10.1007/978-1-59745-194-9_10
Download citation
DOI: https://doi.org/10.1007/978-1-59745-194-9_10
Publisher Name: Humana Press
Print ISBN: 978-1-58829-877-5
Online ISBN: 978-1-59745-194-9
eBook Packages: Springer Protocols